Contrastingly, the LIBRETTO-001 trial displayed a higher representation of patients with RET fusion-positive pancreatic adenocarcinoma, accounting for 26.7% (12 out of 45 patients) of the study cohort5. Here, RET is linked to pancreatic adenocarcinoma.